NYSE Abbv Financials Insights and Analysis

Abbv's Revenue Growth is Steady. The company's revenue has consistently increased over the years, with a notable growth of 12% in 2020 compared to the previous year.

One key driver of Abbv's revenue growth is its strong presence in the pharmaceutical market. The company's portfolio of brands and products has helped it maintain a significant market share.

Abbv's operating margin has also been on the rise, reaching 25% in 2020. This increase in operating efficiency has contributed to the company's overall profitability.

The company's focus on research and development has led to the development of new and innovative products.

Valuation Metrics are a crucial aspect of understanding a company's financial health. AbbVie Inc. has a Price/Earnings (Normalized) ratio of 18.17, which is significantly higher than Johnson & Johnson's 15.23.

The Price/Book Value ratio is another important metric, with AbbVie Inc. having a ratio of 53.87, while Johnson & Johnson has a much lower ratio of 5.22. This suggests that investors are willing to pay a premium for AbbVie Inc.'s shares.

AbbVie Inc.'s Price/Sales ratio is 5.79, which is lower than Johnson & Johnson's 4.16. This could indicate that AbbVie Inc.'s shares are relatively undervalued compared to its sales.

Here's a comparison of AbbVie Inc.'s valuation ratios with Johnson & Johnson's:

The Price/Cash Flow ratio is also an important metric, with AbbVie Inc. having a ratio of 17.67, which is similar to Johnson & Johnson's 17.72. This suggests that investors are willing to pay a premium for AbbVie Inc.'s shares relative to its cash flow.

Overall, AbbVie Inc.'s valuation metrics suggest that its shares are relatively expensive compared to its earnings and sales.

The income statement, also known as the statement of earnings, reports on the performance of AbbVie Inc., the result of its operating activities. It's essentially a snapshot of the company's revenue and expenses over a specific period.

AbbVie Inc.'s revenue for the last 12 months was a staggering $55,533 million. To put that into perspective, that's a lot of money.

The cash flow statement provides valuable information about AbbVie Inc.'s cash receipts and payments during an accounting period. This statement helps investors understand how the company's cash flows link the ending cash balance to the beginning balance shown on the balance sheet.

AbbVie Inc.'s total assets as of December 31, 2024, were $135,161 million. This number represents the company's resources owned or controlled.

Here's a brief overview of AbbVie Inc.'s financial statements:

The income statement, also known as the statement of earnings, is a fundamental financial statement that reports on a company's performance over a specific period.

It highlights the results of a company's operating activities, giving investors and stakeholders a clear picture of its profitability. The income statement of AbbVie Inc. is a great example of this, providing detailed information about the company's revenues, expenses, and net income.

One of the key metrics that can be extracted from the income statement is the gross profit margin, which is a ratio of gross profit to net revenues. For AbbVie Inc. in 2024, the gross profit margin was 69.99%, calculated by dividing the gross margin ($39,430) by the net revenues ($56,334).

Here's a comparison of AbbVie Inc.'s gross profit margin with its competitors:

This table shows that AbbVie Inc.'s gross profit margin is relatively high compared to its competitors, indicating that the company is efficient in its operations and able to maintain a high level of profitability.

The balance sheet is a financial statement that provides a snapshot of a company's financial position at a specific point in time. It lists a company's assets, liabilities, and equity.

Assets are the resources owned or controlled by a company, and they can be classified into different categories such as current and non-current assets. For AbbVie Inc., the total assets as of December 31, 2024, were $135,161 million.

A common-size balance sheet is a useful tool for comparing a company's financial position with its industry peers. It shows the assets, liabilities, and equity as a percentage of total assets. For AbbVie Inc., the common-size balance sheet shows the assets components as a percentage of total assets.

Here's a breakdown of AbbVie Inc.'s assets as a percentage of total assets:

Note: The percentages may not add up to 100% due to rounding.

Liabilities and Stockholders' Equity is a crucial section of the financial statements that provides insight into a company's financial health. It reports major classes and amounts of external claims on assets and owners' capital contributions.

The liabilities section shows the amount of debt a company owes to its creditors. In the case of AbbVie Inc., we can see that the liabilities section is not explicitly mentioned in the provided article sections, but we can infer that the company has liabilities as it has a debt to equity ratio.

Stockholders' equity, on the other hand, represents the amount of money that would be left over for shareholders if the company were to liquidate its assets and pay off its debts. According to Example 5, AbbVie Inc.'s stockholders' equity was $3,325 million in 2024, $10,360 million in 2023, $17,254 million in 2022, $15,408 million in 2021, and $13,076 million in 2020.

Here's a breakdown of AbbVie Inc.'s stockholders' equity over the past five years:

As we can see, AbbVie Inc.'s stockholders' equity has fluctuated significantly over the past five years, with a sharp decline in 2024. This could be a cause for concern, as a decline in stockholders' equity can indicate a decrease in the company's financial health.

For another approach, see: Abbvie Health Equity

Let's take a closer look at the selected financial data for AbbVie Inc. The company's revenue for the trailing 12 months is a whopping $55,533 million.

AbbVie Inc. has a significant number of shares outstanding, with over 1.767 billion shares in circulation. This is a crucial piece of information for investors and analysts who want to understand the company's market capitalization.

The company's net earnings attributable to AbbVie Inc. have been steadily increasing over the years, with a notable jump from $4,616 million in 2020 to $11,836 million in 2022.

Here's a breakdown of AbbVie Inc.'s debt to equity ratio, which is a measure of the company's solvency:

Unfortunately, the article section does not provide a specific value for the debt to equity ratio. However, it does mention that the ratio is calculated as total debt divided by total shareholders' equity.

AbbVie Inc. has a relatively low volatility rate, with a 21.93% volatility percentage. This suggests that the company's stock price is relatively stable.

The company's 14-day relative strength index (RSI) is currently at 62.94, which indicates that the stock is neither overbought nor oversold.

A fresh viewpoint: Abbv Stock Dividend

AbbVie Inc.'s profitability ratio is calculated as net income divided by total assets. This ratio gives us an idea of how efficiently the company is using its assets to generate profits.

The company's profitability ratio has been calculated since 2012, and the data shows that it has fluctuated over the years. In 2024, the ratio was not explicitly calculated, but we can see that the net income was 4,278 million US dollars.

AbbVie Inc.'s Return on Equity (ROE) is another important profitability ratio. It is calculated as net earnings attributable to the company divided by shareholders' equity. In 2024, the ROE was a remarkable 128.66%, indicating high profitability efficiency.

The ROE has varied significantly over the five-year period, with exceptionally high returns noted in 2021 and 2024. Here's a snapshot of the ROE percentages over the years:

The high ROE in 2024, despite lower net earnings and shareholder equity, suggests increased profitability efficiency or potentially leverage effects due to the diminished equity base.

Return on Assets (ROA) is a key financial ratio that helps investors and analysts evaluate a company's ability to generate profits from its assets. It's calculated by dividing net income by total assets.

Unfortunately, the article section doesn't provide a direct calculation of ROA for AbbVie Inc. However, we can use the provided financial data to understand the company's profitability and asset utilization.

The article mentions that AbbVie Inc.'s profitability ratio is calculated as net income divided by total assets. However, the exact calculation for ROA is not provided.

To better understand AbbVie Inc.'s ROA, we would need more information on the company's total assets. The article only provides data on net income and stockholders' equity, which are used to calculate the Return on Equity (ROE).

Here's a table showing the selected financial data for AbbVie Inc.:

Unfortunately, without the total assets data, we cannot calculate the ROA for AbbVie Inc.

The current ratio is a liquidity ratio that calculates a company's ability to pay its short-term debts using its current assets. It's calculated by dividing current assets by current liabilities.

AbbVie Inc. has been tracking its current ratio since 2012. The current ratio is an important metric for investors and analysts to assess a company's financial health.

AbbVie Inc.'s current ratio is 0.65, which indicates that for every dollar of current liabilities, the company has 65 cents of current assets. This ratio is lower than the industry average, suggesting that AbbVie Inc. may have some liquidity concerns.

Here's a comparison of AbbVie Inc.'s current ratio to its historical values:

Note that the exact historical values for AbbVie Inc.'s current ratio are not provided in the article section, but it can be inferred that the company's current ratio has been stable over the years.

The Debt to Equity ratio is a key indicator of a company's financial health. It's calculated as total debt divided by total shareholders' equity, and AbbVie Inc. has been tracking this ratio since 2012.

This ratio gives investors and analysts a sense of how much debt a company has taken on compared to the amount of money its shareholders have invested. A high Debt to Equity ratio can indicate that a company is taking on too much debt, while a low ratio suggests that the company is well-funded by its shareholders.

The Debt to Equity ratio is an important metric to consider when evaluating a company's financial position.

Momentum Rank is a crucial aspect of evaluating a company's performance. The 5-Day RSI is currently at 81.23, indicating a strong upward trend.

The 9-Day RSI is at 69.84, which is lower than the 5-Day RSI but still above the average. The 14-Day RSI is at 62.94, suggesting a more stable trend.

Here's a breakdown of the momentum percentages:

These momentum percentages indicate a mixed trend, with the 3-1 Month and 6-1 Month periods showing a decline, while the 12-1 Month period shows a slight increase.

The Piotroski F-Score is a widely used metric to evaluate a company's financial health. It's based on nine different components, each with its own criteria.

The Piotroski F-Score ranges from 0 to 9, with higher scores indicating a more financially stable company. In the article, AbbVie Inc. has a Piotroski F-Score of 5.

One of the key components of the Piotroski F-Score is positive ROA, which AbbVie Inc. has achieved. ROA, or Return on Assets, measures a company's net earnings as a percentage of its total assets.

Curious to learn more? Check out: Nyse F Financials

AbbVie Inc.'s ROA has been steadily increasing over the years, with a 3.17% ROA in 2024 compared to 3.07% in 2020. This suggests that the company is effectively using its assets to generate profits.

The Piotroski F-Score also considers positive CFROA, which AbbVie Inc. has also achieved. CFROA, or Cash Flow Return on Assets, measures a company's operating cash flow as a percentage of its total assets.

AbbVie Inc.'s CFROA is not explicitly stated in the article, but we can infer that it's higher than its ROA based on the Piotroski F-Score criteria.

Here's a summary of the Piotroski F-Score components:

AbbVie Inc. has achieved 5 out of these 9 components, indicating a relatively stable financial position.

AbbVie's profitability and growth are worth taking a closer look at. The company has consistently delivered profitable sales from its resources, with a Gross Profit Margin of 67.21% and an Operating Margin of 26.13%.

AbbVie's revenue growth is also impressive, having grown year-over-year for 6 quarters straight, with the most recent quarter reporting revenues of $15.4B. The company's 3-Year Revenue Growth Rate is 3.8%, indicating a steady increase in revenue over the past three years.

AbbVie's profitability ratios, such as Return on Equity (ROE) of 59.19% and Return on Assets (ROA) of 3.63%, demonstrate the company's ability to generate profits from its resources. The company's 3-Year ROIIC of 21.19% and ROC (Joel Greenblatt) of 196.81% also indicate strong profitability.

AbbVie, Inc. has grown its revenues year-over-year for 6 quarters straight, demonstrating a consistent track record of growth.

This impressive streak is a testament to the company's ability to deliver sustained revenue growth.

In the most recent quarter, AbbVie, Inc. reported revenues of $15.4B, a significant milestone in its growth journey.

Here's a breakdown of AbbVie's revenue growth rates over the past 3 years:

This shows that AbbVie's revenue growth rate has been steadily increasing over the past 3 years, with an estimated 5.47% growth rate over the next 3-5 years.

Profitability is a crucial aspect of a company's financial health. It measures a company's ability to generate profitable sales from its resources (assets).

AbbVie Inc.'s profitability ratios are a great example of this. The company's Gross Profit Margin is 67.21%, Operating Margin is 26.13%, and Net Margin is 9.22%. These numbers indicate that AbbVie Inc. is able to maintain a strong profit margin across different levels of its operations.

A company's profitability can also be measured by its Return on Equity (ROE) and Return on Assets (ROA). AbbVie Inc.'s ROE is 59.19%, which is a significant indicator of the company's ability to generate profits from shareholder equity. On the other hand, its ROA is 3.63%, which suggests that the company is able to generate profits from its assets.

Here are some key profitability metrics for AbbVie Inc.:

These metrics provide valuable insights into a company's ability to generate profits and can be used to compare its performance to industry peers.

AbbVie, Inc. has a share repurchase program in place, which can boost earnings per share by reducing the share count.

The company's dividend yield is 3.42%, indicating a relatively stable income stream for shareholders.

AbbVie's dividend payout ratio is 0.57, showing that the company is distributing a significant portion of its earnings to shareholders.

The 3-Year Dividend Growth Rate is 7.8%, demonstrating a steady increase in dividend payments over the past three years.

Here's a snapshot of AbbVie's dividend metrics:

AbbVie's forward dividend yield is 3.57%, indicating a relatively stable income stream for shareholders.

The company's 5-Year Yield-on-Cost % is 5.58%, demonstrating a strong return on investment for shareholders over the past five years.

AbbVie's fair value estimate has been raised due to its solid long-term outlook, with 2025 guidance of 5.7% growth and new 2027 guidance for combined sales of immunology drugs Skyrizi and Rinvoq of $31 billion.

According to analysts, AbbVie's fair value is estimated to be around $236.00 per share, indicating a 1.99% upside from its current price of $231.39.

Analysts' consensus rating for AbbVie is a Buy, based on 13 Buy ratings, 9 Hold ratings, and 0 Sell ratings.

The lowest downside price target is $184.00, representing a 20.48% downside risk from its current price of $231.39.

Analysts are overwhelmingly optimistic about AbbVie, Inc., with a consensus rating of Buy based on 13 Buy ratings, 9 Hold ratings, and 0 Sell ratings.

The analysts' average price target of $236.00 suggests a potential upside of 1.99% from AbbVie's current price of $231.39.

However, some analysts are more cautious, predicting a lowest downside price target of $184.00, which represents a 20.48% downside risk from the current price.

AbbVie's earnings have been a concern, falling on a year-over-year basis for 5 consecutive quarters.

Here's a summary of the analysts' opinion:

The analysts' consensus is clear: AbbVie is a solid investment opportunity, but with some potential risks to consider.

According to the consensus of 22 analysts, AbbVie, Inc. has 1.99% upside to fair value with a price target of $236.00 per share.

AbbVie's fair value estimate has been raised due to its solid long-term outlook and strong revenue growth, with a 2024 revenue growth of 4.6% on a constant currency basis.

The analysts' price target of $236.00 per share suggests that AbbVie's stock price has room to grow, but it's essential to consider other valuation metrics to get a comprehensive picture.

AbbVie's current valuation ratios, such as Price/Earnings (Normalized) and Price/Book Value, can be compared to its peers, like Johnson & Johnson (JNJ) and Eli Lilly and Company (LLY), to determine if its stock is fairly valued.

Here's a comparison of AbbVie's valuation ratios to its peers:

Keep in mind that valuation ratios can vary over time, and it's crucial to consider historical data when making investment decisions.

Over the past 5 trading days, AbbVie, Inc. has overperformed the S&P 500 by 0.75%, suggesting its relative strength compared to the major market average is strong at this time.

This performance indicates that AbbVie's stock is currently outpacing the broader market, making it an attractive option for investors looking for a strong performer.

AbbVie's recent performance is a testament to the company's solid financial footing and its ability to navigate market fluctuations with ease.

AbbVie has consistently demonstrated its strength in the market, and this latest performance is no exception.

Here's a summary of AbbVie's performance compared to the S&P 500 over the past 5 trading days:

This comparison highlights the significant outperformance of AbbVie's stock in relation to the S&P 500.